Zephyrnet Logo

Tag: Biogen

Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease to the U.S....

TOKYO and CAMBRIDGE, Mass., Apr 1, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Eisai submitted to the...

Top News

“LEQEMBI Intravenous Infusion” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan

TOKYO and CAMBRIDGE, Mass., Sept 25, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated...

Biogen, continuing executive revamp, finds a new research head

Biogen has hired a new head of research, announcing Wednesday an appointment that the biotechnology company believes will help expand its work beyond the...

North Carolina: a beacon of life sciences innovation and discovery – Bio.News

North Carolina has established itself as a powerhouse in the life sciences sector, fostering a vibrant ecosystem of innovation, research, and cutting-edge advancements. With...

FDA documents hint at ‘uphill battle’ for broad approval of Sage’s depression drug

The Food and Drug Administration's decision last month not to approve a new treatment for one of the most common forms of depression was,...

The Future of Medtech: Exploring the Impact of Layoffs on Innovation and Advancements – iData Research

In an age of rapid technological advancements, the medtech industry stands at the forefront of innovation. From artificial intelligence and robotics to telemedicine and...

Aug. 14 Quick Takes: Second bidder drove up price in Biogen-Reata deal

ARTICLE | DealsPlus: Approval for Pfizer’s MM bispecific and updates from Harmony-Zynerba, One Bio-Hengrui, Taysha, Arcturus, BioXcel  By BioCentury Staff August 15, 2023 12:16 AM UTC Discussions...

Biopharma sector still growing despite layoff wave, Stifel report finds

Dive Brief: The number of biopharmaceutical jobs is growing despite the sector’s market turbulence, but the gains are concentrated to larger companies, according to a...

2023 shaping up to be biggest year for biopharma M&A since pandemic (NYSE:PFE)

The IPO market may still be frigid, but 2023 is shaping up to be the biggest year for biopharma...

July 25 Quick Takes: Biogen cutting 1,000 jobs

ARTICLE | FinancePlus: Stoke falls on Dravet update and updates from Astellas-PeptiDream, Kiniksa and A-Alpha By BioCentury Staff July 26, 2023 12:38 AM UTC As part of its “Fit...

Stoke faces new doubts in search for ‘Spinraza for epilepsy’

Dive Brief: Stoke Therapeutics on Tuesday revealed study results from a pair of small, mid-stage trials testing a medicine designed to target the underlying cause...

Week Ahead – Bracing for next week’s earnings, rate decisions, and major economic data – MarketPulse

US The Fed is expected to resume raising rates at the July 26th FOMC meeting.  Fed funds futures see a 96% chance that the...

Cannabis ER Visits

Cannabis ER visits rose during the covid hysteria, according to the Centers for Disease Control and Prevention (CDC).The CDC’s report found that cannabis-related emergency...

Latest Intelligence

spot_img
spot_img

Chat with us

Hi there! How can I help you?